Friday, 17 Aug 2018

You are here

Biologic Use in Adult-Onset Still's Disease

 Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.

Currently there are no drugs (including biologics) specifically approved for use in AOSD, yet there are several that approved for use in SoJIA - indicated for use in active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older:  

Approved Biologics for SoJIA

  • Ilaris (canakinumab) 
  • Actemra (tocilizumab) 

Biologics Not Approved (but occassionally used)

  • Arcalyst (rilonacept) is an interleukin-1 blocker 
  • Kineret (anakinra): is an IL-1 receptor antagonist

Biologics Under Study (according to clinicaltrials.gov)

  • Ilaris (canakinumab) - under study for AOSD
  • Kineret (anakinra): under study for AOSD and SoJIA

A recent systematic review of the literature identified those biologic drugs that have been studied in AOSD. The meta-analysis included 19 observational studies and showed overall rate of clinical response of 0.85 (95% CI: 0.77-0.91, p < 0.0001) and an overall rate of complete remission of 0.66 (95% CI: 0.54-0.77, p = 0.01). These studies were hampered by a high rate of heterogeneity (Q=59.82 with df=19.0,p<0.0001,I2=68.23%).

Most of these results are driven by the success of IL-1 or IL-6 inhibition in controlling the systemic features of Still's disease - including fever, rash, hepatosplenomegaly, lymphadenopathy, arthritis, serositis and aggressively inflammatory indices.

TNF inhibitors are NOT effective enough to warrant use in those with active inflammatory systemic disease, but may be considered in those whose disease has settled into a dominant rheumatoid-like chronic, polyarthritis.

Disclosures: 
The author has received research/grant financial support on this subject

Add new comment

More Like This

Success of Stopping Depends on the Biologic

The type of biologic disease-modifying anti-rheumatic drug (DMARD) being used and remission duration were important factors predicting whether remission was maintained among patients with rheumatoid arthritis after cessation of the biologic, a Japanese study found.

IL-1 Suppression May Improve Dilated Cardiomyopathy

 

Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

IL-23 Inhibitor Fails in Ankylosing Spondylitis

A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.

Five Barriers to Biosimilar Adoption in the US

A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.